<DOC>
	<DOCNO>NCT00334659</DOCNO>
	<brief_summary>The purpose study confirm apricitabine induce clinically significant effect upon electrocardiogram ( ECG ) parameter dose consistent maximum exposure expect occur clinical practice .</brief_summary>
	<brief_title>A Study Investigate Cardiovascular Safety Apricitabine Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Healthy male subject 18 65 year age , inclusive . Body mass index ( BMI ) 1830 kg/m2 , inclusive , total body weight &gt; 50 kg . No clinically significant medical history . No clinically significant finding complete physical examination , include blood pressure , pulse rate 12lead ECG . Normal clinical safety laboratory result screen . Willing able sign inform consent document indicate understand purpose procedure require study willingness participate study . Willing able stay clinic inpatient activity require protocol . Evidence clinically relevant pathology could interfere study result put subject 's safety risk . Current recurrent disease may affect action , absorption disposition study treatment , clinical laboratory assessment . Current relevant previous history serious , severe unstable ( acute progressive ) physical psychiatric illness , medical disorder require treatment may make subject unlikely fully complete study , condition present undue risk study treatment procedure . History febrile illness within 5 day prior first dose . Positive Hepatitis B surface antigen , Hepatitis C antibody HIV test result screen visit . Use prescription medication within 7 day 5 halflives ( whichever longer ) prior first dose trial medication study . As exception , acetaminophen may use dos â‰¤ 1 g/day . Use overthecounter ( OTC ) medication within 7 day 5 halflives ( whichever longer ) prior study . Herbal supplement ( include herbal weightloss `` metabolism booster '' therapy ) must discontinue 28 day prior first dose trial medication . Known suspected intolerance hypersensitivity study drug , closely related compound state ingredient . Subjects history regular alcohol consumption exceed 14 drinks/week ( 1 drink = 5 ounce [ 150 ml ] wine , 12 ounce [ 360 ml ] beer 1.5 ounce [ 45 ml ] hard liquor ) illicit substance abuse within 6 month screen . Positive screen alcohol drug abuse screen visit study checkin . History evidence routine use tobacco nicotinecontaining product excess 5 cigarette per day ( equivalent ) . Participated clinical study involve investigational drug within 30 day 5 halflives ( whichever longer ) prior study drug administration . Blood donation one pint within 56 day start study . Plasmapheresis plasma donation within 30 day start study . Single 12lead ECG demonstrate QTc &gt; 450 msec screen . A single repeat ECG may do investigator 's discretion . Any condition opinion investigator would complicate compromise study , wellbeing subject .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>HIV-1 Infection</keyword>
</DOC>